Arvinas Inc.

ARVN | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.30

+$0.01 (+0.12%)

At close: Sep 21, 2026, 4:00 PM ET

$8.30

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.12%

(1D)

Rating

Updated: Aug 26, 2026

46.5

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $535.53M

1D Range

8.20 8.38

52W Range

6.97 14.51

Valuation (TTM)

PE 51.88

PB 0.95

EV/EBITDA -11.06

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $14.17

Cash Flow

FCF Yield -52.1%

SBC Adj. FCF Yield -59.2%

SBC Impact -13.6%

Margins

Gross Margin 96.4%

Operating Margin -4.5%

FCF Margin -88.2%

Growth (CAGR)

Revenue 3Y | 5Y 26.0% | 72.4%

Dil EPS 3Y | 5Y 132.8% | 43.0%

FCF 3Y | 5Y -10.4% | -114.8%

Returns

ROA 1.4%

ROE 1.9%

ROIC -2.2%

Financial Health

Net Cash

$567.6M

Current Ratio 7.91

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. ...

Sector Healthcare

Industry Biotechnology

Employees 246

IPO Date Sep 26, 2018

Website www.arvinas.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$13

Upside

+56.63%

Buy (6)

Hold (1)

Sell (1)

Analyst Details ➞